The biopharmaceutical company’s drug in development is designed to treat gastrointestinal stromal tumors (GIST). Read More
British pharma giant GSK to acquire U.S. drug developer IDRx in $1.15 billion deal
Published:
Published:
The biopharmaceutical company’s drug in development is designed to treat gastrointestinal stromal tumors (GIST). Read More